19 results on '"Bangdiwala, Ananta"'
Search Results
2. Implications of excess weight on kidney donation: Long-term consequences of donor nephrectomy in obese donors.
- Author
-
Serrano, Oscar K., Sengupta, Bodhisatwa, Bangdiwala, Ananta, Vock, David M., Dunn, Ty B., Finger, Erik B., Pruett, Timothy L., Matas, Arthur J., and Kandaswamy, Raja
- Abstract
Background An elevated body mass index (>30 kg/m
2 ) has been a relative contraindication for living kidney donation; however, such donors have become more common. Given the association between obesity and development of diabetes, hypertension, and end-stage renal disease, there is concern about the long-term health of obese donors. Methods Donor and recipient demographics, intraoperative parameters, complications, and short- and long-term outcomes were compared between contemporaneous donors—obese donors (body mass index ≥30 kg/m2 ) versus nonobese donors (body mass index <30 kg/m2 ). Results Between the years 1975 and 2014, we performed 3,752 donor nephrectomies; 656 (17.5%) were obese donors. On univariate analysis, obese donors were more likely to be older (P <.01) and African American (P <.01) and were less likely to be a smoker at the time of donation (P =.01). Estimated glomerular filtration rate at donation was higher in obese donors (115 ± 36 mL/min/1.73m2 ) versus nonobese donors (97 ± 22 mL/min/1.73m2 ; P <.001). There was no difference between groups in intraoperative and postoperative complications; but intraoperative time was longer for obese donors (adjusted P <.001). Adjusted postoperative length of stay (LOS) was longer (adjusted P =.01), but after adjustment for donation year, incision type, age, sex, and race, there were no differences in short-term (<30 days) and long-term (>30 days) readmissions. Estimated glomerular filtration rate and rates of end-stage renal disease were not significantly different between donor groups >20 years after donation (P =.71). However, long-term development of diabetes mellitus (adjusted hazard ratio (HR) 3.14; P <.001) and hypertension (adjusted hazard ratio (HR) 1.75; P <.001) was greater among obese donors and both occurred earlier (diabetes mellitus: 12 vs 18 years postnephrectomy; hypertension: 11 vs 15 years). Conclusion Obese donors develop diabetes mellitus and hypertension more frequently and earlier than nonobese donors after donation, raising concerns about increased rates of end-stage renal disease. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
3. Technical procedures and REDCap tools for internet-based clinical trials.
- Author
-
Bangdiwala, Ananta S. and Boulware, David R.
- Subjects
- *
COVID-19 , *CORONAVIRUS disease treatment , *CLINICAL trials , *DATABASE management - Abstract
In March of 2020 our team of researchers developed and opened three clinical trials to investigate hydroxychloroquine as prophylaxis or treatment for the coronavirus disease 2019 (COVID-19). We simultaneously built corresponding Research Electronic Data Capture (REDCap) projects for these low-touch, remote trials that relied on participant-reported data. REDCap has built-in features that support pragmatic, internet-based studies, and REDCap is flexible enough to allow creative solutions for specific trials. We describe challenges, choices, and suggestions based on our experience with REDCap for our COVID-19 trials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Absence of cerebrospinal fluid pleocytosis in tuberculous meningitis is a common occurrence in HIV co-infection and a predictor of poor outcomes.
- Author
-
Cresswell, Fiona V., Bangdiwala, Ananta S., Meya, David B., Bahr, Nathan C., Vidal, Jose E., Török, M. Estée, Thao, Le Thi Phuong, Thwaites, Guy E., and Boulware, David R.
- Subjects
- *
HIV infections , *CEREBROSPINAL fluid , *TUBERCULOUS meningitis - Published
- 2018
- Full Text
- View/download PDF
5. 426: Neonatal morbidity and complication rates in the super-super-obese.
- Author
-
Kim, Tana, Burn, Sabrina C., Bangdiwala, Ananta, Pace, Samantha, Rauk, Phillip N., and Lupo, Virginia R.
- Subjects
NEONATAL diseases ,BODY mass index ,OBESITY in women ,CHI-squared test ,HEALTH outcome assessment - Published
- 2017
- Full Text
- View/download PDF
6. 287: Exploratory research on first and second trimester urinary metabolic profiles and fetal growth restriction.
- Author
-
Luthra, Gauri, Vuckovic, Ivan, Redmon, J. Bruce, Gray, Heather, Bangdiwala, Ananta, Shields, Andrea, Macura, Slobodan, and Nair, K. Sreekumaran
- Subjects
FETAL growth retardation ,SECOND trimester of pregnancy ,GESTATIONAL age ,FIRST trimester of pregnancy ,EXPLORATORY factor analysis ,STATISTICAL correlation - Published
- 2017
- Full Text
- View/download PDF
7. Risk Factors for Developing Adult Cardiovascular Disease in Children Who Received a Kidney Transplant: Analysis of 1,055 Kidney Transplants between 1963-2015 at a Single Institution.
- Author
-
Serrano, Oscar K., Bangdiwala, Ananta, Vock, David, Dunn, Ty B., Chinnakotla, Srinath, Finger, Erik, Kandaswamy, Raja, Pruett, Timothy L., Matas, Arthur J., and Chavers, Blanche
- Subjects
- *
CARDIOVASCULAR diseases risk factors , *KIDNEY transplantation , *JUVENILE diseases , *IMMUNOSUPPRESSION , *AZATHIOPRINE - Published
- 2016
- Full Text
- View/download PDF
8. Delineating Optimal Surgical Performance in Laparoscopic Donor Nephrectomy among Transplant Surgery Fellows: A Learning Curve Analysis.
- Author
-
Serrano, Oscar K., Bangdiwala, Ananta, Vock, David, Kirchner, Varvara A., Berglund, Danielle, Dunn, Ty B., Finger, Erik, Pruett, Timothy L., Matas, Arthur J., and Kandaswamy, Raja
- Subjects
- *
KIDNEY transplantation , *NEPHRECTOMY , *LAPAROSCOPIC surgery , *BLOOD loss estimation , *KIDNEY blood-vessels , *LEARNING curve - Published
- 2016
- Full Text
- View/download PDF
9. Risk Factors for Developing Post-Transplant Malignancy in Children Who Receive a Kidney Transplant: Analysis of 1,055 Kidney Transplants between 1963 and 2015 at a Single Institution.
- Author
-
Serrano, Oscar K., Bangdiwala, Ananta, Vock, David, Dunn, Ty B., Chinnakotla, Srinath, Finger, Erik, Kandaswamy, Raja, Pruett, Timothy L., Matas, Arthur J., and Chavers, Blanche
- Subjects
- *
KIDNEY transplantation , *CANCER risk factors , *PROPORTIONAL hazards models , *LYMPHOPROLIFERATIVE disorders , *ORGAN donors - Published
- 2016
- Full Text
- View/download PDF
10. Vancomycin-resistant Enterococcal Bloodstream Infections in Hematopoietic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies: Impact of Daptomycin MICs of 3 to 4 mg/L.
- Author
-
Chong, Pearlie P., van Duin, David, Bangdiwala, Ananta, Ivanova, Anastasia, Miller, William C., Weber, David J., Gilligan, Peter H., and Shea, Thomas C.
- Abstract
Purpose Case reports of treatment failure with standard-dose daptomycin (6 mg/kg) have recently surfaced in vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI) episodes with daptomycin MICs of 3 to 4 mg/L. The clinical implications of daptomycin MICs of 3 to 4 mg/L in VRE BSIs have not been elucidated. Methods We performed a single institutional retrospective analysis of adult stem cell transplant recipients and patients with hematologic malignancies diagnosed with VRE BSI from 2006 to 2014 and compared outcomes between those with daptomycin MICs of 3 to 4 mg/L those with 2 mg/L, as determined by Etest. Findings Forty-two daptomycin-treated VRE BSI episodes, all due to Enterococcus faecium were identified; 19 episodes with daptomycin MICs of 3 to 4 mg/L and 23 episodes with a daptomycin MIC of 2 mg/L. Patients in the higher daptomycin MIC group were more likely to be male, to be stem cell transplant recipients, and to have received high-dose daptomycin treatment (>6 mg/kg). In unadjusted analyses, microbiological failure in the daptomycin MICs 3 to 4 mg/L versus 2 mg/L groups (odds ratio = 1.79, 95% CI, 0.52–6.11; P = 0.35), the median duration of bacteremia (4 days in daptomycin MICs 3–4 mg/L vs 3 days in daptomycin MIC 2 mg/L; P = 0.18) and all-cause 30-day mortality (21% in daptomycin MICs 3–4 mg/L vs 35% in daptomycin MIC 2 mg/L group; P = 0.49) were not different. In adjusted analyses, the association between higher Pitt bacteremia scores and all-cause 30-day mortality was statistically significant ( P = 0.0006), whereas the association between daptomycin MICs of 3 to 4 mg/L and all-cause 30-day mortality approached statistical significance ( P = 0.06). Implications Duration of bacteremia and microbiological failure rates did not differ by daptomycin MICs in VRE BSI episodes in our patients, composed of adult stem cell transplant recipients and patients with hematologic malignancies. There was a nonsignificant trend in multivariable analysis suggesting that all-cause 30-day mortality was lower in patients whose VRE bloodstream isolates were with daptomycin MICs of 3 to 4 mg/L. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study.
- Author
-
Cresswell, Fiona V, Tugume, Lillian, Bahr, Nathan C, Kwizera, Richard, Bangdiwala, Ananta S, Musubire, Abdu K, Rutakingirwa, Morris, Kagimu, Enock, Nuwagira, Edwin, Mpoza, Edward, Rhein, Joshua, Williams, Darlisha A, Muzoora, Conrad, Grint, Daniel, Elliott, Alison M, Meya, David B, Boulware, David R, and ASTRO-CM team
- Subjects
- *
TUBERCULOUS meningitis , *NEUROLOGICAL disorders , *SYMPTOMS , *LONGITUDINAL method , *COMMUNICABLE diseases , *CEREBROSPINAL fluid - Abstract
Introduction: Tuberculous meningitis accounts for 1-5% of tuberculosis cases. Diagnostic delay contributes to poor outcomes. We evaluated the performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis diagnosis.Methods: In this prospective validation study, we tested the cerebrospinal fluid (CSF) of adults presenting with suspected meningitis (ie, headache or altered mental status with clinical signs of meningism) to the Mulago National Referral Hospital and Mbarara Regional Referral Hospital in Uganda. We centrifuged the CSF, resuspended the cell pellet in 2 mL CSF, and tested 0·5 mL aliquots with Xpert Ultra, Xpert MTB/RIF (Xpert), and mycobacterial growth indicator tube (MGIT) culture. We quantified diagnostic performance against the uniform case definition of probable or definite tuberculous meningitis and a composite microbiological reference standard.Findings: From Nov 25, 2016, to Jan 24, 2019, we screened 466 adults with suspected meningitis and tested 204 for tuberculous meningitis. Uniform clinical case definition classified 51 participants as having probable or definite tuberculous meningitis. Against this uniform case definition, Xpert Ultra had 76·5% sensitivity (95% CI 62·5-87·2; 39 of 51 patients) and a negative predictive value of 92·7% (87·6-96·2; 153 of 165), compared with 55·6% sensitivity (44·0-70·4; 25 of 45; p=0·0010) and a negative predictive value of 85·8% (78·9-91·1; 121 of 141) for Xpert and 61·4% sensitivity (45·5-75·6; 27 of 44; p=0·020) and negative predictive value of 85·2% (77·4-91·1; 98 of 115) for MGIT culture. Against the composite microbiological reference standard, Xpert Ultra had sensitivity of 92·9% (80·5-98·5; 39 of 42), higher than Xpert at 65·8% (48·6-80·4; 25 of 38; p=0·0063) and MGIT culture at 72·2% (55·9-86·2; 27 of 37; p=0·092). Xpert Ultra detected nine tuberculous meningitis cases missed by Xpert and MGIT culture.Interpretation: Xpert Ultra detected tuberculous meningitis with higher sensitivity than Xpert and MGIT culture in this HIV-positive population. However, with a negative predictive value of 93%, Xpert Ultra cannot be used as a rule-out test. Clinical judgment and novel highly sensitive point-of-care tests are still required.Funding: Wellcome Trust, National Institute of Health, National Institute of Neurologic Diseases and Stroke, Fogarty International Center, and National Institute of Allergy and Infectious Diseases. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.
- Author
-
Rhein, Joshua, Huppler Hullsiek, Kathy, Tugume, Lillian, Nuwagira, Edwin, Mpoza, Edward, Evans, Emily E, Kiggundu, Reuben, Pastick, Katelyn A, Ssebambulidde, Kenneth, Akampurira, Andrew, Williams, Darlisha A, Bangdiwala, Ananta S, Abassi, Mahsa, Musubire, Abdu K, Nicol, Melanie R, Muzoora, Conrad, Meya, David B, Boulware, David R, and ASTRO-CM team
- Abstract
Background: Identifying new antifungals for cryptococcal meningitis is a priority given the inadequacy of current therapy. Sertraline has previously shown in vitro and in vivo activity against cryptococcus. We aimed to assess the efficacy and cost-effectiveness of adjunctive sertraline in adults with HIV-associated cryptococcal meningitis compared with placebo.Methods: In this double-blind, randomised, placebo-controlled trial, we recruited HIV-positive adults with cryptococcal meningitis from two hospitals in Uganda. Participants were randomly assigned (1:1) to receive standard therapy with 7-14 days of intravenous amphotericin B (0·7-1·0 mg/kg per day) and oral fluconazole (starting at 800 mg/day) with either adjunctive sertraline or placebo. Sertraline was administered orally or via nasogastric tube at a dose of 400 mg/day for 2 weeks, followed by 200 mg/day for 12 weeks, then tapered off over 3 weeks. The primary endpoint was 18-week survival, analysed by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT01802385.Findings: Between March 9, 2015, and May 29, 2017, we screened 842 patients with suspected meningitis and enrolled 460 of a planned 550 participants, at which point the trial was stopped for futility. Three patients in the sertraline group and three patients in the placebo group were lost to follow-up and therefore discontinued before study end. At 18 weeks, 120 (52%) of 229 patients in the sertraline group and 106 (46%) of 231 patients in the placebo group had died (hazard ratio 1·21, 95% CI 0·93-1·57; p=0·15). The fungal clearance rate from cerebrospinal fluid was similar between groups (0·43 -log10 CFU/mL per day [95% CI 0·37-0·50] in the sertraline group vs 0·47 -log10 CFU/mL per day [0·40-0·54] in the placebo group; p=0·59), as was occurrence of grade 4 or 5 adverse events (72 [31%] of 229 vs 75 [32%] of 231; p=0·98), most of which were associated with amphotericin B toxicity.Interpretation: Sertraline did not reduce mortality and should not be used to treat patients with HIV-associated cryptococcal meningitis. The reasons for sertraline inactivity appear to be multifactorial and might be associated with insufficient duration of therapeutic sertraline concentrations.Funding: National Institutes of Health and Medical Research Council, Wellcome Trust. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
13. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.
- Author
-
Bahr, Nathan C, Nuwagira, Edwin, Evans, Emily E, Cresswell, Fiona V, Bystrom, Philip V, Byamukama, Adolf, Bridge, Sarah C, Bangdiwala, Ananta S, Meya, David B, Denkinger, Claudia M, Muzoora, Conrad, Boulware, David R, and ASTRO-CM Trial Team
- Subjects
- *
MENINGITIS diagnosis , *TUBERCULOUS meningitis , *HIV-positive persons , *CEREBROSPINAL fluid , *MENINGITIS treatment , *MYCOBACTERIA , *HIV infection complications , *COMPARATIVE studies , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MOLECULAR diagnosis , *MYCOBACTERIUM , *RESEARCH , *RESEARCH funding , *EVALUATION research - Abstract
Background: WHO recommends Xpert MTB/RIF as initial diagnostic testing for tuberculous meningitis. However, diagnosis remains difficult, with Xpert sensitivity of about 50-70% and culture sensitivity of about 60%. We evaluated the diagnostic performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis.Methods: We prospectively obtained diagnostic cerebrospinal fluid (CSF) specimens during screening for a trial on the treatment of HIV-associated cryptococcal meningitis in Mbarara, Uganda. HIV-infected adults with suspected meningitis (eg, headache, nuchal rigidity, altered mental status) were screened consecutively at Mbarara Regional Referral Hospital. We centrifuged CSF, resuspended the pellet in 2 mL of CSF, and tested 0·5 mL with mycobacteria growth indicator tube culture, 1 mL with Xpert, and cryopreserved 0·5 mL, later tested with Xpert Ultra. We assessed diagnostic performance against uniform clinical case definition or a composite reference standard of any positive CSF tuberculous test.Findings: From Feb 27, 2015, to Nov 7, 2016, we prospectively evaluated 129 HIV-infected adults with suspected meningitis for tuberculosis. 23 participants were classified as probable or definite tuberculous meningitis by uniform case definition, excluding Xpert Ultra results. Xpert Ultra sensitivity was 70% (95% CI 47-87; 16 of 23 cases) for probable or definite tuberculous meningitis compared with 43% (23-66; 10/23) for Xpert and 43% (23-66; 10/23) for culture. With composite standard, we detected tuberculous meningitis in 22 (17%) of 129 participants. Xpert Ultra had 95% sensitivity (95% CI 77-99; 21 of 22 cases) for tuberculous meningitis, which was higher than either Xpert (45% [24-68]; 10/22; p=0·0010) or culture (45% [24-68]; 10/22; p=0·0034). Of 21 participants positive by Xpert Ultra, 13 were positive by culture, Xpert, or both, and eight were only positive by Xpert Ultra. Of those eight, three were categorised as probable tuberculous meningitis, three as possible tuberculous meningitis, and two as not tuberculous meningitis. Testing 6 mL or more of CSF was associated with more frequent detection of tuberculosis than with less than 6 mL (26% vs 7%; p=0·014).Interpretation: Xpert Ultra detected significantly more tuberculous meningitis than did either Xpert or culture. WHO now recommends the use of Xpert Ultra as the initial diagnostic test for suspected tuberculous meningitis.Funding: National Institute of Neurologic Diseases and Stroke, Fogarty International Center, National Institute of Allergy and Infectious Disease, UK Medical Research Council/DfID/Wellcome Trust Global Health Trials, Doris Duke Charitable Foundation. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).
- Author
-
Sperduto, Paul W., Jiang, Wen, Brown, Paul D., Braunstein, Steve, Sneed, Penny, Wattson, Daniel A., Shih, Helen A., Bangdiwala, Ananta, Shanley, Ryan, Lockney, Natalie A., Beal, Kathryn, Lou, Emil, Amatruda, Thomas, Sperduto, William A., Kirkpatrick, John P., Yeh, Norman, Gaspar, Laurie E., Molitoris, Jason K., Masucci, Laura, and Roberge, David
- Subjects
- *
MELANOMA prognosis , *MELANOMA diagnosis , *BRAIN metastasis , *BIOMARKERS , *RETROSPECTIVE studies , *AGE distribution , *BRAIN tumors , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *MELANOMA , *PROGNOSIS , *REGRESSION analysis , *RESEARCH , *RESEARCH funding , *TRANSFERASES , *GENETIC markers , *EVALUATION research , *KARNOFSKY Performance Status - Abstract
Purpose: To update the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for a markedly heterogeneous patient population, patients with melanoma and brain metastases, using a larger, more current cohort, including molecular markers.Methods: The original Melanoma-GPA is based on data from 483 patients whose conditions were diagnosed between 1985 and 2005. This is a multi-institutional retrospective database analysis of 823 melanoma patients with newly diagnosed brain metastases from January 1, 2006, to December 31, 2015. Multivariable analyses identified significant prognostic factors, which were weighted and included in the updated index (Melanoma-molGPA). Multiple Cox regression was used to select and weight prognostic factors in proportion to their hazard ratios to design the updated Melanoma-molGPA in which scores of 4.0 and 0.0 are associated with the best and worst prognoses, as with all of the diagnosis-specific GPA indices. Log-rank tests were used to compare adjacent classes.Results: There were 5 significant prognostic factors for survival (age, Karnofsky performance status [KPS], extracranial metastases [ECM], number of brain metastases, and BRAF status), whereas only KPS and the number of brain metastases were significant in the original Melanoma-GPA. Median survival improved from 6.7 to 9.8 months between the 2 treatment eras, and the median survival times for patients with Melanoma-molGPA of 0 to 1.0, 1.5 to 2.0, 2.5 to 3.0, and 3.5 to 4.0 were 4.9, 8.3, 15.8, and 34.1 months (P<.0001 between each adjacent group).Conclusions: Survival and our ability to estimate survival in melanoma patients with brain metastases has improved significantly. The updated Melanoma-molGPA, a user-friendly tool to estimate survival, will facilitate clinical decision making regarding whether and which treatment is appropriate and will also be useful for stratification of future clinical trials. To further simplify use, a free online/smart phone app is available at brainmetgpa.com. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
15. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
- Author
-
Sperduto, Paul W., Jiang, Wen, Brown, Paul D., Braunstein, Steve, Sneed, Penny, Wattson, Daniel A., Shih, Helen A., Bangdiwala, Ananta, Shanley, Ryan, Lockney, Natalie A., Beal, Kathryn, Lou, Emil, Amatruda, Thomas, Sperduto, William A., Kirkpatrick, John P., Yeh, Norman, Gaspar, Laurie E., Molitoris, Jason K., Masucci, Laura, and Roberge, David
- Subjects
- *
CANCER treatment , *METASTASIS , *TREATMENT of brain cancer , *BRAIN cancer patients , *MELANOMA treatment , *PATIENTS - Abstract
Purpose: Brain metastases are a common problem in patients with melanoma, but little is known about the effect of gene mutations on survival in these patients.Methods and Materials: We created a retrospective multi-institutional database of 823 patients with melanoma and brain metastases diagnosed between 2006 and 2015. Clinical parameters, gene mutation status (BRAF, C-KIT, NRAS), and treatment were correlated with survival. Treatment patterns and outcomes were compared with a prior era (1985-2005).Results: BRAF status was known in 584 of 823 patients (71%). BRAF, NRAS, and C-KIT mutations were present in 51%, 22%, and 11% of tested patients, respectively. The median time from primary diagnosis to brain metastasis was 32 months, and overall median survival (MS) from the time of initial treatment of brain metastases was 10 months. MS for BRAF-positive and BRAF-negative patients was 13 months and 9 months, respectively (P=.02). There was no significant difference in MS in patients with or without NRAS or C-KIT mutations. The time from primary diagnosis to brain metastasis did not vary by mutation and was not associated with survival after the diagnosis of brain metastases. MS for the 1985 to 2005 and 2006 to 2015 cohorts was 6.7 months and 10.0 months, respectively (P<.01). Reflecting treatment-trend changes, use of whole-brain radiation therapy decreased from 48% to 26% during this period. Among BRAF-positive patients, 71% received targeted BRAF and/or MEK inhibitors and 57% received some combination of targeted therapy, chemotherapy, and/or immunotherapy.Conclusions: For melanoma patients with brain metastases, BRAF-positive patients survive longer than BRAF-negative patients and overall survival has improved from 1985-2005 to 2006-2015. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
16. Post-Transplant Malignancy after Pediatric Kidney Transplantation: Retrospective Analysis of Incidence and Risk Factors in 884 Patients Receiving Transplants Between 1963 and 2015 at the University of Minnesota.
- Author
-
Serrano, Oscar K., Chinnakotla, Srinath, Dunn, Ty B., Finger, Erik B., Kandaswamy, Raja, Pruett, Timothy L., Najarian, John S., Matas, Arthur J., Bangdiwala, Ananta S., Vock, David M., and Chavers, Blanche M.
- Subjects
- *
COMPLICATIONS from organ transplantation , *KIDNEY transplantation , *TRANSPLANTATION of organs, tissues, etc. in children , *AZATHIOPRINE , *CANCER - Abstract
Background: Post-transplant malignancy (PTM) remains a concern among pediatric kidney transplant (PKT) recipients.Study Design: Between 1963 and 2015, 884 pediatric (age 0 to 17 years old) patients received 1,055 PKTs at our institution. Cox proportional hazards models were constructed to identify risk factors for PTM after PKT with time-to-first-PTM as a primary outcome. Secondly, the hazard of death or graft loss was calculated in patients who developed PTM.Results: Median patient survival was 33 years (interquartile range [IQR] 18.7 to 47 years); 260 patients died during the study period and 47 had been diagnosed with PTM. There were 235 PTMs that occurred in 136 (15.4%) recipients at a median age of 29 years (IQR 17.8 to 37 years). The percentages of patients with PTM were 13% at 20 years post-PKT and 26% at 30 years post-PKT. Of PTM patients who died, 63.8% died of PTM. Among those who developed PTM, there was a higher hazard of death or graft loss (hazard ratio [HR] 1.62; 95% CI 1.11 to 2.38). In multivariable proportional hazards models, factors associated with PTM were increasing age at PKT (adjusted HR [AHR] 3.14; 95% CI 1.80 to 5.48 for 14 to 17 year-olds compared with children less than 3 years), having a living unrelated donor (LURD; AHR 3.25; 95% CI 1.27 to 8.35 compared with a living related donor), or implanting an Epstein-Barr virus (EBV)-positive allograft in an EBV-negative recipient (AHR 5.66; 95% CI 1.11 to 29.0). Compared with the general population, the cancer rate for PKT recipients was 6 times higher (126 vs 21 per 100,000 person-years).Conclusions: Pediatric kidney transplant recipients are at increased risk of PTM, which adversely affects survival. Children receiving transplants at an older age, from a LURD, or who receive an EBV-positive organ, should be monitored closely for the development of PTM. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.
- Author
-
Sperduto, Paul W., Yang, T. Jonathan, Beal, Kathryn, Pan, Hubert, Brown, Paul D., Bangdiwala, Ananta, Shanley, Ryan, Yeh, Norman, Gaspar, Laurie E., Braunstein, Steve, Sneed, Penny, Boyle, John, Kirkpatrick, John P., Mak, Kimberley S., Shih, Helen A., Engelman, Alex, Roberge, David, Arvold, Nils D., Alexander, Brian, and Awad, Mark M.
- Subjects
- *
PROTEIN-tyrosine kinases , *PROTEIN kinases , *ADENOCARCINOMA , *CANCER treatment , *METASTASIS , *PATIENTS - Abstract
Purpose: Lung cancer remains the most common cause of both cancer mortality and brain metastases (BM). The purpose of this study was to assess the effect of gene alterations and tyrosine kinase inhibition (TKI) on median survival (MS) and cause of death (CoD) in patients with BM from lung adenocarcinoma (L-adeno).Methods: A multi-institutional retrospective database of patients with L-adeno and newly diagnosed BM between 2006 and 2014 was created. Demographics, gene alterations, treatment, MS, and CoD were analyzed. The treatment patterns and outcomes were compared with those in prior trials.Results: Of 1521 L-adeno patients, 816 (54%) had known alteration status. The gene alteration rates were 29%, 10%, and 26% for EGFR, ALK, and KRAS, respectively. The time from primary diagnosis to BM for EGFR-/+ was 10/15 months (P=.02) and for ALK-/+ was 10/20 months (P<.01), respectively. The MS for the group overall (n=1521) was 15 months. The MS from first treatment for BM for EGFR and ALK-, EGFR+, ALK+ were 14, 23 (P<.01), and 45 (P<.0001) months, respectively. The MS after BM for EGFR+ patients who did/did not receive TKI before BM was 17/30 months (P<.01), respectively, but the risk of death was not statistically different between TKI-naïve patients who did/did not receive TKI after the diagnosis of BM (EGFR/ALK hazard ratios: 1.06 [P=.84]/1.60 [P=.45], respectively). The CoD was nonneurologic in 82% of patients with known CoD.Conclusion: EGFR and ALK gene alterations are associated with delayed onset of BM and longer MS relative to patients without these alterations. The CoD was overwhelmingly nonneurologic in patients with known CoD. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
18. Impact of Daptomycin Minimum Inhibitory Concentration (MIC) on Outcomes of Patients with Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT) Recipients with Vancomycin-Resistant Enterococci (VRE) Bloodstream Infection (BSI).
- Author
-
Chong, Pearlie P., van Duin, David, Bangdiwala, Ananta, Ivanova, Anastasia, Kerr, Alan, Weber, David J., Gilligan, Peter H., Khan, Tippu, and Shea, Thomas C.
- Subjects
- *
ENZYME inhibitors , *HEALTH outcome assessment , *HEMATOLOGIC malignancies , *HEMATOPOIETIC stem cell transplantation , *VANCOMYCIN resistance , *MEDICAL care - Published
- 2015
- Full Text
- View/download PDF
19. Evaluation of the Impact of Anti-Thymocyte Globulin (ATG) on Post-Hematopoietic Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT.
- Author
-
Kaminski, Katie S., Beechinor, Ryan, Lebovic, Rachel, Roth, Mary, Bangdiwala, Ananta, Ballarini, Nicolas, Ivanova, Anastasia, Chong, Pearlie P., Jamieson, Katarzyna, Shea, Thomas C., and Rao, Kamakshi V.
- Subjects
- *
THYMOCYTES , *GLOBULINS , *HEMATOPOIETIC stem cell transplantation , *HEALTH outcome assessment , *GRAFT versus host disease , *MYELOSUPPRESSION - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.